Shenzhen Neptunus Bioengineering (000078.SZ): NEP018 tablet receives a notice of approval for drug clinical trial.

Shenzhen Neptunus Bioengineering (000078.SZ) announced that its wholly-owned subsidiary, Shenzhen Haiwang Pharmaceutical Technology Research Institute Co., Ltd. (referred to as "Haiwang Pharmaceutical Research Institute"), has recently received the approval and issuance of the NEP018 tablet "Drug Clinical Trial Approval Notice" from the National Medical Products Administration. The approval allows the drug to conduct clinical trials as a single agent in late-stage malignant solid tumors. The NEP018 tablet is a new tumor-targeted small molecule kinase inhibitor independently developed by Haiwang Pharmaceutical Research Institute with proprietary intellectual property rights. Through comprehensive preclinical research, the NEP018 tablet has shown good selective inhibitory activity against its designated targets, with a good inhibitory effect on gastrointestinal tumors. With a concentration of pharmacokinetic tissue distribution in the gastrointestinal tract, and considering the current situation where the treatment of gastrointestinal tumors mainly relies on chemotherapy drugs with additional biologic drugs, the development of this project can help address the unmet clinical needs for targeted small molecule drugs for gastrointestinal tumors. The core patent of this project has already been granted invention patent authorization.